Navigation Links
STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Date:1/15/2008


PARIS, January 15 /PRNewswire-FirstCall/ --

(EURO Millions) 2007 2006 07/06

% % %

Sales Sales Change

Southern Europe(1) 31.99 74.3 27.97 74.7 14

Other EU Countries (2) 9.66 22.4 8.22 22.0 17

Other Markets 1.40 3.3 1.27 3.3 10

SLIT 34.55 80.3 28.75 76.8 20

SCIT 7.12 16.5 6.86 18.3 4

Other Products 1.38 3.2 1.85 4.9 (25)

Total Q4 Sales 43.05 100.0 37.46 100.0 15

Southern Europe (1) 109.15 74.2 93.68 74.0 17

Other EU Countries (2) 32.49 22.1 28.00 22.1 16

Other Markets 5.42 3.7 4.87 3.9 11

FY Sales 147.06 100.0 126.55 100.0 16

SLIT 116.43 79.2 96.30 76.1 21

SCIT 24.90 16.9 24.09 19.0 3

Other Products 5.73 3.9 6.16 4.9 (7)

FY Cumulated Sales 147.06 100.0 126.55 100.0 16

(1) Portugal, Spain, France, Italy, Greece; (2) including Switzerland

Sales growth and financial position

2007 4th quarter sales registered a further 15% growth in all markets. 2007 full-year growth was 16%, driven by the strength of the sublingual route desensitisation segment (SLIT), which grew 21%. The significant increase in the number of new patients, in particular in France and Germany, and growing sales excluding subsidiaries were the main growth drivers.

2007 results, should exceed those of 2006 (EBIT of EUR 23 million), in spite of a further significant increase in R&D expenses.

2008 outlook

The Group gives guidance of double-digit sales growth. 2008 results should be impacted by additional R&D investments in the US.

The questions asked by the German agency regarding the ORALAIR(R) Grasses file have been dealt with and we expect a licence to be issued.

Talks are continuing with potential partners in the US.

About STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis, rhinitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

StallergEnes realised 2007 sales of EUR 147 million, of which half outside France.

StallergEnes' shares are listed on Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on StallergEnes, please visit our website: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
2. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
3. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
4. SAFC Hitech(TM) Plans Further Expansion Into Asia
5. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
6. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
7. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
10. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
11. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this ... Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at ...
(Date:2/10/2016)... ... 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on ... today it has been selected to present at the Cavendish Global Health Impact Forum ... The purpose of the Forum is to help family offices and foundations develop ...
(Date:2/9/2016)... ... 08, 2016 , ... Date and time: March 1, 2016, ... Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. ... hold an open house for participants to learn about a new Master of ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy of ... it is offering its 2016 AAT Member Certification Qualification Course for Technicians via a ... the webinar, which will include a detailed review of hardware, software, and camera setup/operations, ...
Breaking Biology Technology:
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
Breaking Biology News(10 mins):